









Mercado
/
Acciones
/
nasdaq-twst
/

Twist Bioscience Corp

TWST

28.850USD

-4.830-14.34%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

1.73BCap. mercado

PérdidaP/E TTM



Twist Bioscience Corp

28.850

-4.830-14.34%

Descripción general Compañía Finanzas

Finanzas

Más Datos de Twist Bioscience Corp Compañía

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. It is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. It makes products for use across many industries, including healthcare, industrial chemicals, agriculture and academic research.

Información de la empresa

Símbolo de cotizaciónTWST

Nombre de la empresaTwist Bioscience Corp

Fecha de salida a bolsaOct 31, 2018

Director ejecutivoDr. Emily M. Leproust, Ph.D.

Número de empleados923

Tipo de seguridadOrdinary Share

Fin del año fiscalOct 31

Dirección681 Gateway Blvd.

CiudadSOUTH SAN FRANCISCO

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal94080

Teléfono18007190671

Sitio Webhttps://www.twistbioscience.com/

Símbolo de cotizaciónTWST

Fecha de salida a bolsaOct 31, 2018

Director ejecutivoDr. Emily M. Leproust, Ph.D.

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Emily M. Leproust, Ph.D.

Chairman of the Board, Chief Executive Officer

341.19K

-0.14%

Mr. Patrick John Finn, Ph.D.

President, Chief Operating Officer

113.61K

-2.10%

Mr. Keith L. Crandell

Independent Director

92.71K

+5.07%

Mr. Dennis Cho

Chief Legal Officer and Corporate Secretary

50.03K

-0.25%

Ms. Paula Green

Senior Vice President - Human Resources

47.07K

-0.30%

Mr. Nelson C. Chan

Independent Director

22.25K

+25.16%

Dr. Melissa A. Starovasnik, Ph.D.

Independent Director

15.81K

+39.44%

Mr. Jan Johannessen

Independent Director

12.60K

+55.04%

Mr. Adam Laponis

Chief Financial Officer

8.25K

-22.88%

Mr. Robert Werner

Chief Accounting Officer, Vice President

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Emily M. Leproust, Ph.D.

Chairman of the Board, Chief Executive Officer

341.19K

-0.14%

Mr. Patrick John Finn, Ph.D.

President, Chief Operating Officer

113.61K

-2.10%

Mr. Keith L. Crandell

Independent Director

92.71K

+5.07%

Mr. Dennis Cho

Chief Legal Officer and Corporate Secretary

50.03K

-0.25%

Ms. Paula Green

Senior Vice President - Human Resources

47.07K

-0.30%

Mr. Nelson C. Chan

Independent Director

22.25K

+25.16%

Desglose de ingresos

Divisa: USDActualizado: dom., 6 de jul

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

NGS tools

51.15M

55.12%

Synthetic genes

28.22M

30.41%

Antibody discovery

5.70M

6.14%

Oligo pools

4.71M

5.08%

DNA libraries

3.02M

3.25%

Por regiónUSD

Nombre

Ganancia

Proporción

Americas

55.19M

59.48%

EMEA

30.64M

33.02%

APAC

6.96M

7.50%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

NGS tools

51.15M

55.12%

Synthetic genes

28.22M

30.41%

Antibody discovery

5.70M

6.14%

Oligo pools

4.71M

5.08%

DNA libraries

3.02M

3.25%

Estadísticas de accionistas

Actualizado: mar., 20 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

ARK Investment Management LLC

10.68%

The Vanguard Group, Inc.

9.77%

Artisan Partners Limited Partnership

9.77%

BlackRock Institutional Trust Company, N.A.

7.73%

William Blair Investment Management, LLC

6.52%

Other

55.53%

Accionistas

Proporción

ARK Investment Management LLC

10.68%

The Vanguard Group, Inc.

9.77%

Artisan Partners Limited Partnership

9.77%

BlackRock Institutional Trust Company, N.A.

7.73%

William Blair Investment Management, LLC

6.52%

Other

55.53%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

61.44%

Investment Advisor/Hedge Fund

39.92%

Hedge Fund

8.43%

Research Firm

3.10%

Individual Investor

1.97%

Pension Fund

1.40%

Bank and Trust

0.41%

Sovereign Wealth Fund

0.27%

Family Office

0.24%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

574

70.28M

117.29%

-746.72K

2025Q1

585

70.23M

117.22%

-1.63M

2024Q4

578

67.47M

113.11%

-8.03M

2024Q3

588

67.80M

115.74%

-8.48M

2024Q2

579

66.59M

114.39%

-10.53M

2024Q1

565

68.18M

117.94%

-8.61M

2023Q4

559

67.81M

117.39%

-11.70M

2023Q3

560

68.09M

118.66%

-11.36M

2023Q2

577

69.42M

121.49%

-5.07M

2023Q1

593

64.77M

113.93%

-4.20M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

ARK Investment Management LLC

6.24M

10.42%

-140.57K

-2.20%

Mar 31, 2025

The Vanguard Group, Inc.

5.85M

9.77%

+60.28K

+1.04%

Mar 31, 2025

Artisan Partners Limited Partnership

5.85M

9.77%

-42.31K

-0.72%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

4.63M

7.73%

+9.40K

+0.20%

Mar 31, 2025

William Blair Investment Management, LLC

3.81M

6.35%

+857.14K

+29.06%

Mar 31, 2025

Invesco Advisers, Inc.

3.34M

5.57%

-197.51K

-5.59%

Mar 31, 2025

State Street Global Advisors (US)

2.69M

4.5%

+149.68K

+5.88%

Mar 31, 2025

Nikko Asset Management Co., Ltd.

2.42M

4.03%

-197.17K

-7.55%

Mar 31, 2025

Thrivent Asset Management, LLC

1.51M

2.51%

+532.04K

+54.64%

Dec 31, 2024

Point72 Asset Management, L.P.

1.43M

2.39%

+1.43M

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

ARK Genomic Revolution ETF

7.54%

iShares Genomics Immunology and Healthcare ETF

4.75%

Global X Genomics & Biotechnology ETF

2.67%

WisdomTree BioRevolution Fund

2.24%

ARK Innovation ETF

2.09%

Franklin Genomic Advancements ETF

1.79%

ROBO Global Healthcare Technology & Innovation ETF

1.75%

BNY Mellon Innovators ETF

0.77%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.73%

SPDR S&P Biotech ETF

0.7%

ARK Genomic Revolution ETF

Proporción7.54%

iShares Genomics Immunology and Healthcare ETF

Proporción4.75%

Global X Genomics & Biotechnology ETF

Proporción2.67%

WisdomTree BioRevolution Fund

Proporción2.24%

ARK Innovation ETF

Proporción2.09%

Franklin Genomic Advancements ETF

Proporción1.79%

ROBO Global Healthcare Technology & Innovation ETF

Proporción1.75%

BNY Mellon Innovators ETF

Proporción0.77%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proporción0.73%

SPDR S&P Biotech ETF

Proporción0.7%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

